Avalyn Pharma (NASDAQ:AVLN) Stock Rating Upgraded by Jefferies Financial Group

Avalyn Pharma (NASDAQ:AVLN) was upgraded by Jefferies Financial Group to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other equities analysts have also recently issued reports on the company. Guggenheim assumed coverage on Avalyn Pharma in a research report on Monday. They issued a “buy” rating and a $80.00 price objective on the stock. Evercore assumed coverage on Avalyn Pharma in a research note on Tuesday. They issued an “outperform” rating and a $51.00 price target for the company. Wall Street Zen raised Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Finally, Morgan Stanley began coverage on Avalyn Pharma in a report on Tuesday. They issued an “overweight” rating and a $53.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Strong Buy” and an average target price of $59.00.

Avalyn Pharma Stock Down 7.4%

NASDAQ:AVLN opened at $26.70 on Monday. Avalyn Pharma has a 52 week low of $25.05 and a 52 week high of $32.22.

Insiders Place Their Bets

In other news, Director Jill Carroll purchased 277,778 shares of the stock in a transaction dated Friday, May 1st. The shares were purchased at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the acquisition, the director directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This represents a 14.55% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was purchased at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the purchase, the insider owned 2,186,562 shares in the company, valued at approximately $39,358,116. The trade was a 34.06% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.